Back to Top Skip to main content Skip to sub-navigation

COVID-19 Booster Shots are Now Available – What You Need to Know

Image of Containers of the Pfizer COVID-19 vaccine. Each vial contains six doses for vaccination against the COVID-19 virus. Click to open a larger version of the image. Pfizer vaccines at Moody Air Force Base, Georgia, Sept. 9, 2021. Each Pfizer vial contains six doses for vaccination against the COVID-19 virus. (U.S. Air Force photo by Senior Airman Rebeckah Medeiros)

Recommended Content:

Coronavirus and the COVID-19 Vaccine | Coronavirus | COVID-19 Vaccine Efforts

Booster shots of Pfizer-BioNTech's COVID-19 vaccine are now available at military medical treatment facility and Department of Defense vaccination sites.

Those eligible for a Pfizer-BioNTech booster shot may also get them at commercial sites, such as civilian pharmacies or doctors' offices

All COVID-19 vaccines, including Pfizer-BioNTech's booster dose, may be given at the same time as the influenza vaccine (or other vaccines which may be due).

Fully vaccinated is still defined by the Centers for Disease Control and Prevention (CDC) as completing the 2-dose series for Pfizer-BioNTech or Moderna vaccines and the 1 dose for Johnson & Johnson/Janssen vaccine.

Booster Shots

Booster shots are now formally recommended for certain groups of people under an Emergency Use Authorization, according to recent announcements from the Food and Drug Administration (FDA) and the CDC.

For now, eligibility for a booster shot is limited to those who previously received a two-dose Pfizer-BioNTech COVID-19 vaccine for their initial vaccination.

At this time, booster shots are not recommended for those who initially received the Moderna two-dose vaccine and the Johnson & Johnson/Janssen single-dose vaccine or a mixed series of vaccines. However, those two populations will likely be recommended to receive a booster shot, and a formal recommendation for that may be forthcoming later this year as additional data are reviewed, according to the CDC.

Eligibility to voluntarily receive a single Pfizer-BioNTech booster vaccine includes people who are:

  • 65 years and older and residents in long-term care facilities
  • 18 and older in long-term care settings
  • 50-64 with underlying medical conditions
  • 18-49 with underlying medical conditions based on their individual benefits and risks
  • 18-64 who are at increased risk of COVID-19 exposure and transmission because of occupational or institutional settings such as teachers, frontline health care workers and essential workers, and those incarcerated, based on their individual benefits and risks.

To become eligible for a booster shot, there is a there is a six-month waiting period after the completion of the second dose of the Pfizer-BioNTech 2-dose vaccine.

Booster doses are not currently part of the DOD or federal worker mandates for COVID-19 vaccine requirements.

Proof of an underlying condition or an occupational risk is not required to receive a booster dose at an MTF or DOD vaccination site, and self-reporting of a condition eligible for a booster shot is allowed at any site where vaccines are available.

Comirnaty

The Pfizer-BioNTech COVID-19 vaccine is also known as the "Pfizer-BioNTech Comirnaty vaccine." The initial Pfizer-BioNTech vaccine was authorized for use under an FDA Emergency Use Authorization earlier this year, and the same vaccine assumed the new name, Pfizer-BioNTech Comirnaty, when it was fully approved by the FDA on Sept. 23. The two vaccines may be used interchangeably.

The COVID-19 shot being administered
Air Force Maj. Carla Cox, 59th Medical Wing commander’s executive officer, provides a COVID-19 vaccine to a San Antonio Military Health System beneficiary at Wilford Hall Ambulatory Surgical Center, Joint Base San Antonio-Lackland, Texas. (U.S. Air Force photo by Staff Sgt. Amanda Stanford)

The Comirnaty name (pronounced koe-mir' na tee) was developed from taking the Co from COVID-19, followed by the mRNA in the middle and ending with the 'ty' as a nod to immunity and community.

Third Shot vs. Booster

There is an important distinction between "booster shots" and "an additional dose."

A booster shot of the Pfizer-BioNTech COVID-19 vaccine is recommended for certain individuals at least six months after the second dose of the two dose Pfizer-BioNTech series. A booster shot aims to increase, or "boost", waning immunity observed over time, especially in those 65 years and older and residents of long-term care facilities. A familiar analogy of a booster shot may be the tetanus booster that is recommended every 10 years.

The option for an "additional dose" of mRNA vaccine (Pfizer-BioNTech or Moderna) was recommended in August for a comparatively smaller group of people who have compromised immune systems. This, unlike the booster dose, is because the primary 2-dose series of Pfizer-BioNTech or Moderna may not have resulted in a good enough antibody response; therefore an additional dose is recommended. The timing of an "additional dose" is at least 28 days after the second dose of an mRNA vaccine.

What about Moderna or Janssen Booster Doses?

Health officials may soon make a decision about whether to expand the recommendation for a booster beyond just those who received the Pfizer-BioNTech vaccine.

Moderna has already submitted data to the FDA for booster authorization. "A decision is expected soon," National Institutes of Health Director Francis Collins said Sept. 28. Earlier in September, J&J/Janssen submitted new data in support of a booster for its vaccine.

It's Time to Get Vaccinated

Both FDA and CDC noted that the populations most vulnerable to the SARS-CoV-2 coronavirus that causes COVID-19 continue to be those who are unvaccinated, and the nation's priority should remain getting everyone vaccinated with their primary series.

The approved and authorized COVID-19 vaccines continue to be effective in reducing severe, cases, hospitalizations, and deaths, even against the dominant Delta variant.

Most COVID-19 severe cases, hospitalizations, and deaths occur among the unvaccinated, around 99% of the time.

Hospitalizations rates are 10 to 22 times higher among unvaccinated adults compared to vaccinated adults, according to the CDC.

The CDC's Advisory Committee on Immunization Practices and the FDA Vaccines and Related Biologicals Advisory Committee will continue to follow the scientific data, and evidence will inform booster shot recommendations beyond the current ones.

Experts are looking at all available data to understand how well current vaccines are working for different populations - including looking at new variants Delta and Mu - to see how they affect vaccines' effectiveness.

While the COVID-19 vaccines currently available work to prevent severe illness, hospitalization, and deaths, public health experts are starting to see reduced protection, especially among certain populations, against mild to moderate disease.

"FDA and CDC have determined these booster shots can begin, based on the latest data and evidence, after a thorough, independent and transparent process of evaluating safety and effectiveness," the White House said in a Sept. 24 statement.

You also may be interested in...

Communication to ABA Providers Regarding Continued Temporary Authorization to Utilize Telehealth for CPT Code 97156 During the COVID-19 National Emergency

Publication
6/3/2020

TRICARE is announcing the continuation of the temporary exception to policy regarding the use of synchronous telehealth (TH) capabilities (both audio and video) for Applied Behavior Analysis (ABA) Family Adaptive Behavior Treatment Guidance services specifically during this COVID-19 pandemic.

Recommended Content:

Coronavirus | About TRICARE

Force Health Protection Guidance (Supplement 9) -Department of Defense Guidance for Deployment and Redeployment of Individuals and Units during the Novel Coronavirus Disease 2019 Pandemic

Publication
5/26/2020

This memorandum provides force health protection (FHP) deployment and redeployment guidance for Service members (including Reserve Component (RC) and National Guard members in a title 10 or title 32 duty status) and DoD civilian employees deploying within and outside the United States during the COVID-19 pandemic, consistent with references (a) and (b).

Recommended Content:

Coronavirus

Guidance for Commanders on Risk-Based Changing of Health Protection Condition Levels During the Coronavirus Disease 2019 Pandemic

Publication
5/20/2020

This memorandum provides guidance for commanders to consider when making decisions to change health protection condition (HPCON) levels as COVID-19 pandemic conditions on and adjacent to our installations begin to improve.

Recommended Content:

Coronavirus

Resuming Elective Surgical, Invasive, and Dental Procedures in Military Medical and Dental Treatment Facilities

Publication
5/19/2020

This memorandum provides guidance on how each Military Medical Treatment Facility (MTF) and Dental Treatment Facility (DTF) may resume elective medical and dental procedures.

Recommended Content:

Public Health | Coronavirus

Modification and Reissuance of DoD Response to Coronavirus Disease 2019 -Travel Restrictions

Publication
4/20/2020

All DoD Service members will stop movement, both internationally and domestically, while this memorandum is in effect. All DoD civilian personnel, and dependents of DoD Service members and DoD civilian personnel, whose travel is Government-funded will stop movement, both internationally and domestically, while this memorandum is in effect.

Recommended Content:

Coronavirus

Implementation Guidance for Presidential Memorandum, "Providing Federal Support for Governor's Use of the National Guard to Respond to COVID-19 ," Dated April 7, 2020

Publication
4/14/2020

Recommended Content:

Coronavirus

Benefits Eligibility for 32 USC 502(f) Missions

Publication
4/14/2020

A chart outlining the various Benefits Eligibility for 32 USC 502(f) Missions

Recommended Content:

Coronavirus | About TRICARE

Memorandum on Providing Federal Support for Governors' Use of the National Guard to Respond to COVID-19

Publication
4/14/2020

Recommended Content:

Coronavirus

Delegation of Authority for Reserve Component Activation Authorities during the Coronavirus Disease 2019 Response

Publication
4/10/2020

This delegation assigns to the Service Secretaries the authority to activate Reserve Component personnel and to modify their orders as needed to employ and retain them for the COVID-19 response.

Recommended Content:

Coronavirus

Authorization to Employ Military Medical Capabilities to Treat COVID-19 Patients

Publication
4/8/2020

Effective immediately, the Commander, U.S Northern Command, is authorized, as he deems necessary and appropriate, to employ military medical capabilities under his operational control to treat patients who have contracted coronavirus disease 2019 (COVID-19).

Recommended Content:

Coronavirus

Decision Memorandum on TRICARE Implementation of the "Families First Coronavirus Response Act"

Publication
4/7/2020

The Families First Coronavirus Response Act, Public Law 116-127, Division F, Section 6006(a), limits TRICARE authority to impose copayment or other cost-sharing for novel coronavirus (COVID-19) testing and related provider visits that result in orders for or administration of Food and Drug Administration (FDA) approved, cleared, or authorized diagnostic products. In order for the Defense Health Agency (DHA) to implement, the Assistant Secretary of Defense for Health Affairs (ASD(HA)) must acknowledge the self-executing authority of the statute and direct the Director, DHA, or designee, to issue guidance implementing the statutory provisions.

Recommended Content:

About TRICARE | Coronavirus

DoD Guidance on the Use of Cloth Face Coverings

Publication
4/5/2020

Effective immediately, to the extent practical, all individuals on DoD property, installations, and facilities will wear cloth face coverings when they cannot maintain six feet of social distance in public areas or work centers (this does not include in a Service member's or Service family member's personal residence on a military installation).

Recommended Content:

Coronavirus | Public Health

Policy on Accessions and Accessions Training during the COVID-19 Outbreak

Publication
4/3/2020

The Military Departments must seek ways to maximize accessions in a responsible manner to minimize a reduction in military end strength and the potential deterioration of mid-and long-term readiness and capacity.

Recommended Content:

Coronavirus

Transition of Military Medical Treatment Facilities from Military Departments to the Defense Health Agency during the COVID-19 Response

Publication
4/2/2020

The Department's MTF transition plan is conditions-based. While the transition of MTFs to DHA is continuing, the COVID-19 response requirements are impacting DHA's ability to meet all required conditions. The need for the DHA and MILDEPs to refocus efforts away from the transition to support the COVID-19 response led to questions regarding the future of MTF Transition.

Recommended Content:

Coronavirus | Military Health System Transformation

Pharmacy Guidance for Market MTFs

Publication
3/31/2020

Message to Pharmacy Beneficiaries regarding military pharmacy services during the COVID-19 pandemic.

Recommended Content:

Coronavirus | TRICARE Pharmacy Operations | About TRICARE
<< < 1 2 3 4 5 > >> 
Showing results 46 - 60 Page 4 of 5

DHA Address: 7700 Arlington Boulevard | Suite 5101 | Falls Church, VA | 22042-5101

Some documents are presented in Portable Document Format (PDF). A PDF reader is required for viewing. Download a PDF Reader or learn more about PDFs.